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AbstrAct
Objectives Percutaneous cervical cordotomy 
(PCC) is an interventional ablative procedure in 
the armamentarium for cancer pain treatment, 
but there is limited evidence to support its use. 
This study aimed to assess the effectiveness and 
safety of PCC.
Methods Analysis was undertaken of the irst 
national (UK) prospective data repository of 
adult patients with cancer undergoing PCC for 
pain treatment. The relationship between pain 
and other outcomes before and after PCC was 
examined using appropriate statistical methods.
results Data on 159 patients’ PCCs (performed 
from 1 January 2012 to 6 June 2017 in three 
centres) were assessed: median (IQR) age was 
66 (58–71) years, 47 (30%) were female. 
Mesothelioma was the most common primary 
malignancy (57%). The median (IQR) time from 
cancer diagnosis to PCC assessment was 13.3 
(6.2–23.2) months; PCC to follow- up was 9 
(8–25) days; and survival after PCC was 1.3 (0.6–
2.8) months. The mean (SD) for ‘average pain’ 
using a numerical rating scale was 6 (2) before 
PCC and 2 (2) at follow- up, and for ‘worst pain’ 
9 (1) and 3 (3), respectively. The median (IQR) 
reduction in strong opioid dose at follow- up was 
50% (34–50). With the exception of ‘activity’, 
all health- related quality of life scores (5- level 
version of EuroQol-5 Dimension) either improved 
or were stable after PCC. Six patients (4%) had 
PCC- related adverse events.
conclusions PCC is an effective treatment 
for cancer pain; however, indings in this study 
suggest PCC referrals tended to be late in 
patients’ disease trajectories. Further study into 
earlier treatment and seeking international 
consensus on PCC outcomes will further 
enhance opportunities to improve patient care.
IntrOductIOn
Pain control reduces suffering and 
improves quality of life. The WHO anal-
gesic ladder serves as a foundation for 
the treatment of cancer- related pain.1 
However, in 10%20% of patients, stan-
dard therapies (eg, opioids) are not effec-
tive and other strategies are needed.2 In 
patients with uncontrolled cancer pain, 
interventional techniques, such as percu-
taneous cervical cordotomy (PCC), should 
be considered.3
PCC is a procedure carried out in a 
conscious patient and uses radiofre-
quency ablation to create a heat lesion 
in the lateral spinothalamic tract in the 
upper cervical spinal cord, interrupting 
ascending pain signals.4 A successful 
procedure results in an analgesic area 
below the C4 dermatome on the contra-
lateral side of the body, and therefore may 
have particular utility in pain syndromes 
that are predominantly one sided (eg, 
malignant pleural mesothelioma). The 
goal is to achieve diminished pinprick 
sensation and loss of temperature percep-
tion in the painful region of the body. This 
can be done as an open surgical exposure 
but most commonly is through a percuta-
neous routePCC.
Cordotomy is indicated for unilat-
eral cancer pain in patients with a life 
expectancy of less than 1 year who are 
not responding to other interventions.5 
Beyond this time period, some patients 
can develop neuropathic deafferentation 
pain as a postprocedure complication; and 
as such PCC is only indicated in patients 
with limited life expectancy.5
Despite PCC being an important part 
of the armamentarium for the treatment 
of cancer pain, there is limited evidence 
to support its use. A systematic review by 
our group, focused on the effectiveness 
of PCC in mesothelioma- related pain,6 
found the available evidence is signifi-
cantly limited in quantity and quality. 
There is a lack of clear consensus as to 
whether PCC is most effective for neuro-
pathic, nociceptive or indeed mixed 
pain.7 8 One of the advantages of PCC is 
 o
n
 M
ay 6, 2020 at BVA. Protected by copyright.
http://spcare.bmj.com/
BM
J Support Palliat Care: first published as 10.1136/bmjspcare-2019-002057 on 27 March 2020. Downloaded from 
 2 Poolman M, et al. BMJ Supportive & Palliative Care 2020;0:1–6. doi:10.1136/bmjspcare-2019-002057
Original research
that mobility is preserved (eg, compared with other 
interventions such as neuraxial analgesia that are often 
an alternative option in such cases).9
Although the research done suggests that PCC might 
be safe and effective, more work is needed to inform 
clinical practice and support its continued provi-
sion.6 There is a need for a prospective evaluation 
of the efficacy and complications of PCC for cancer 
pain. Our research group established a national (UK) 
PCC register in 2012. In this register, we prospec-
tively collect key data on all patients who have PCC 
performed for cancer- related pain, both before proce-
dure and at follow- up. Herein we present data from 
the first cohort of patients from the register.
MethOds
Following a UK- wide survey and subsequent Delphi 
process10 focused on the role of PCC in the manage-
ment of mesothelioma, a national PCC data set was 
finalised by the project team. A medical database 
information technology company Dendrite Clinical 
Systems ( www. e- dendrite. com) was requisitioned to 
host the repository.
The registry was launched in January 2012, which 
prospectively collects key preprocedure and follow- up 
data on all patients who have PCC for cancer pain. To 
our knowledge, this is the first national data repository 
for PCC in the world.
Data from this PCC repository register were assessed 
between 1 January 2012 and 6 June 2017. The register 
collected data from three interventional pain centres 
offering cordotomy procedures (Liverpool, Ports-
mouth and Warwick) serving a geographically defined 
population of 60 million. A further centre in Oldham 
was not included within this analysis due to limited 
resources to input data and its subsequent closure in 
2015.
Patients
All patients in the register met the following criteria: 
pathological or radiological diagnosis of cancer; pain 
VHFRQGDU\ WR WKHLU FDQFHU  ZRUVW SDLQ LQ WKH
previous 24 hours) on a 010 numerical rating scale 
(NRS)); PCC indicated following PCC practitioner 
assessment; and over 18 years of age. Additionally, 
the PCC practitioner used their clinical judgement to 
ensure each patient had underwent a reasonable trial 
of opioids and adjuvant medication.
Pcc procedures
The PCC was performed as an inpatient, under fluoro-
scopic guidance (X- ray) and performed by one of five 
pain medicine consultants trained in this technique11 
and regularly undertaking this procedure (minimum 
five procedures per year). The equipment used (needles 
and C- arm for imaging) were from each centres usual 
suppliers, and each centre has a bespoke head support.
Typically, patients required sedation for the proce-
dure using either fentanyl alone, or in combination 
with sedatives (eg, propofol). Patients were placed in 
the supine position with their head and neck stabilised 
in an external fixator (head support). An image inten-
sifier and contrast (after dural puncture) were used to 
identify C1 and C2 vertebrae and the dentate ligament 
on the side contralateral to the pain. A radiofrequency 
electrode was passed into the anterolateral spinal cord 
and the spinothalamic tract then localised through 
sensory stimulation. Incremental heat lesions were 
created in the lateral spinothalamic tract while assess-
ment was made of ipsilateral motor function to ensure 
preservation of the adjacent corticospinal tract. The 
contralateral analgesia was then checked by pinprick 
and the power of the ipsilateral arm and leg was also 
checked between each lesion. If required the proce-
dure was repeated. The total PCC procedure time was 
usually under 60 min, most lasting 3045 min. The 
policy in all study centres was that strong opioid anal-
gesics were reduced by up to 50% of total daily dose 
either immediately before or after procedure.
Assessments
The following were assessed before and after PCC: pain 
(average and worst) using a 010 NRS; health- related 
quality of life using the 5- level version of EuroQol-5 
Dimension (EQ- 5D- 5L) (where a lower score indi-
cates a less negative impact on quality of life and func-
tion, and dimensions include mobility, self- care, usual 
DFWLYLWLHVSDLQGLVFRPIRUWDQ[LHW\GHSUHVVLRQ12; and 
strong opioid medication (morphine equivalent daily 
dose (MEDD) was calculated to allow comparison). 
6LGH HIIHFWVDGYHUVH HYHQWV ZHUH DVVHVVHG GHVFULS-
tively following each procedure and recorded in case 
records. Further presence of specific side effects was 
assessed including urinary retention, opioid toxicity, 
dyspnoea and postprocedure pain at PCC site. Data 
were collected and entered into the registry either by 
the pain specialist nurse or the PCC practitioner.
Analysis
Primarily, a descriptive analysis was undertaken. The 
primary purpose of the repository was data collection 
so formal hypothesis testing and sample size calcu-
lation were not appropriate. However, exploratory 
analyses were undertaken using appropriate non- 
parametric tests. Data checking (to ensure consistency 
with care records) was conducted. Only those patients 
who had data collected as part of the repository were 
assessed. All statistical analyses were performed using 
SPSS V.21.0. Where appropriate, means and SDs, or 
medians and IQR are reported throughout. A p value 
<0.05 was regarded as statistically significant.
results
From 1 January 2012 to 6 June 2017, one hundred 
and fifty- nine patients had a PCC performed and were 
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Table 1 Patient demographics and baseline pain characteristics 
(n=159)
n (%)
Female 47 (30)
Place of care (when patient was referred for PCC)
  Home 109 (69)
  Hospice 39 (25)
  Hospital 10 (6)
  Other 1 (1)
Diagnosis
  Malignant pleural mesothelioma 90 (57)
  Primary lung cancer 43 (27)
  Other cancer 26 (17)
Performance status (ECOG)
  1 36 (23)
  2 61 (38)
  3 59 (35)
  4 3 (2)
Source of referral for PCC
  Specialist palliative care 96 (60)
  Oncology 31 (20)
  Respiratory medicine 14 (9)
  Pain medicine 13 (8)
  General practitioner 3 (2)
  Other 1 (1)
Primary site of pain
  Thorax 136 (86)
  Arm 17 (11)
  Leg 6 (4)
ECOG, Eastern Cooperative Oncology Group; PCC, percutaneous cervical 
cordotomy.
Figure 1 Average and worst pain, before procedure and at 
follow- up (n=159).
Figure 2 5- Level version of EuroQol-5 Dimension (EQ- 5D- 5L), 
before procedure and at follow- up (n=110).
analysed as part of the present study. Patient demo-
graphics and baseline pain characteristics are shown 
in table 1.
The median (IQR) age of patients was 66 (5871) 
years. All but two patients (n=157) were on strong 
opioid analgesia (eg, morphine). The median (IQR) 
strong opioid dose (MEDD) at baseline was 200 mg 
(100400). The median (IQR) time from diagnosis of 
cancer to assessment for consideration of PCC was 
13.3 (6.223.2) months. One hundred and twenty- 
nine patients (81%) had their cordotomy done within 
48 hours of assessment by their PCC practitioner. The 
median (IQR) time to follow- up was 9 (825) days and 
within this time period 137 (87%) patients were alive. 
The median (IQR) duration of survival from proce-
dure was 1.3 (0.62.8) months.
Figure 1 shows the average and worst pain (using a 
010 NRS), before PCC and at follow- up. The mean 
(SD) for average pain was 6 (2) before cordotomy 
and 2 (2) at follow- up, p<0.001 (Wilcoxon signed- 
rank test). The mean (SD) for worst pain was 9 (1) 
before cordotomy and 3 (3) at follow- up, p<0.001 
(Wilcoxon signed- rank test). The median (IQR) reduc-
tion in strong opioid dose at follow- up was 50% 
(3450). (At baseline, median (IQR) MEDD=200 mg 
(100400 mg), at follow- up=140 mg (20300 mg), 
p<0.001 (Kolmogorov- Smirnov test).)
Figure 2 shows the EQ- 5D scores before cordotomy 
and at follow- up. There was an improvement in 
activity after procedure (p=0.018) but a reduction in 
sleep (p<0.01)Wilcoxon signed- rank test. In other 
areas, all patient scores either improved or were stable 
after cordotomy.
Six patients (4%) had adverse events relating to their 
PCC including urinary retention (2) opioid toxicity (1) 
impaired balance (1) dyspnoea (1) and pain at the PCC 
site (1).
dIscussIOn
statement of main indings
The findings from our data repository suggest PCC 
is an effective treatment for patients with cancer- 
related pain and helps facilitate a significant reduction 
in opioid medication. The findings support previous 
observations that cordotomy has an ongoing role in 
the management of unilateral pain due to malignancy 
such as mesothelioma and lung cancer.6 Of equal 
importance is that in terms of PCCs effectiveness for 
improving pain control, its benefits far outweigh its 
risks as shown by the fact that only six patients (4%) 
reported any adverse effects. This aligns with conclu-
sions in previous work noting that serious complica-
tions related directly to the procedure are minimal 
providing the procedure is done by an experienced 
clinician.5 6 Additionally, the overall quality of life for 
patients undergoing PCC improved or was maintained 
at the same level.  on
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It was also observed that patients tended to receive 
the procedure late in their disease trajectory (averaging 
just over a month before their death) and so potentially 
did not receive prolonged benefit from this interven-
tion. Although this may relate to pain control issues 
not being significantly severe to merit a PCC, the 
services as a whole advocate early review to optimise 
procedure timing. It was noteworthy that 20 patients 
died after PCC and before the initial follow- up. This 
observation likely represents real- life clinical practice 
where factors such as overestimation of prognosis, 
uncertain disease trajectory and referrals being made 
too late are occurring. We also hypothesise that the 
lack of familiarity and limited access to PCC services 
may have compounded the aforementioned factors. 
Given the limited survival of these patients, getting the 
timing right for PCC is crucially important.
how this relates to the existing literature
A previous review article summarised six case series, 
totalling 677 patients with cancer, who were treated 
with unilateral cordotomy since 1990.13 Similar bene-
fits to our study in terms of pain control and opioid 
consumption were reported. A further two case series 
(with 41 and 207 participants) have also shown bene-
fits in terms of pain relief for PCC using CT.9 14
Within this study, the most common source of PCC 
referral came from specialist palliative care teams. This 
may reflect the complex nature of the pain, and hence 
the need for specialist input. Alternatively, it may 
reflect a lack of awareness about the availability of the 
procedure. Within the UK, it is important to recognise 
that the number of centres offering PCC has reduced 
in recent years. One of the centres, in Warwick, closed 
in 2015 due to practitioner retirement; a further 
centre in Oldham, not included within this analysis 
due to limited resources to input data, also closed in 
2015. Currently, there are only three centres (Ports-
mouth, Liverpool and, since 2017, Glasgow) which 
offer the procedure, with less than 10 practitioners 
nationally who are trained to perform the procedure. 
This impacts patients, who may already have signif-
icant morbidity from their illness, who then have to 
travel substantial distances to be considered for a PCC. 
Internationally, this decline is also recognised with 
cordotomy being considered a dying art within North 
America and the practice of PCC being infrequently 
used.15 Within the last decade, only three medical 
centres within the USA have reported on their PCC 
performance.16 Globally, unless PCC is highlighted as 
an essential procedure for the management of complex 
pain, and specific teaching provided within specialist 
training programmes, expertise will disappear.
strengths and limitations
This is the first national PCC data repository and one 
of the largest within the last 20 years.17 Although a 
larger case series (n=207) has been published,9 this 
was over a 20- year period, and it was uncertain if the 
data represented national findings. Additionally, we 
have demonstrated the potential strength of this data 
repositoryrecording standardised patient- related 
outcome measures to establish the effectiveness and 
safety of a specific procedure.
The study has several weaknesses. First, the numbers 
are modest as over a 5- year time period, 159 proce-
dures were conducted. Second, the study is observa-
tional in nature, so lacks a comparison or control group 
to be able to draw more definitive conclusions about 
the implications for clinical practice. For example, the 
majority of patients had pain in the thoracic region 
and pain appeared to respond well to PCC. The lack of 
a sufficiently sized comparator group (eg, upper limb 
pain) meant that comparison in efficacy dependent on 
location was not possible, but this would be of interest 
in future work. Third, although pain was assessed, 
other outcomes (eg, effect of physical activity) would 
also be of interest. Additionally, pain characterisation 
was limited; specifically whether pain was predomi-
nantly nociceptive or neuropathic was not consistently 
recorded. As previous work in this area would suggest 
that some pain types may respond better to PCC, 
garnering this in future work would be of importance. 
Finally, the degree of missing data limits the level of 
information provided such as specific details about the 
pain quality, more robust data on non- opioid analge-
sics and the provision of non- pharmacological strate-
gies to manage the pain. More robust and systematic 
collection of data in these areas would be beneficial.
Implications and unanswered questions
Further recognition about the role of PCC within 
the patients trajectory would seem pertinent. With 
patients dying a mean of 1.3 months following PCC, 
potentially patients were not always deriving full 
benefit from the procedure. Additionally, some patients 
died following their initial assessment suggesting that 
there may have been an overestimation of prognosis. 
Hence, one of the key issues relates to the definition of 
clear triggers for considering PCC in a timely manner. 
Generally, PCC tends to be considered for those with 
unilateral pain (especially when secondary to costo-
pleural syndrome), who are experiencing inadequate 
pain control, have dose- limiting adverse effects or a 
combination of both of these factors.5 Alternatively, 
indication for PCC is defined as medically refractory, 
unilateral pain in a patient with an expected lifespan 
of less than one year.15 Patients in the present cohort 
were not referred for cordotomy based on any formal 
criteria. Rather referral was made considering multiple 
factors including patients condition (function and 
prognosis), analgesic therapy, patient and family pref-
erence and ease of travel to the treating centre. Future 
work which highlighted patients most likely to benefit 
from cordotomy would be of interest.
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Although centres were able to offer the procedure 
quickly (81% had PCC within 48 hours of assessment 
by a PCC practitioner) and respond well to patients 
needs, earlier referral for PCC could have provided 
better quality of life for a longer time period. Previous 
consensus work agreed that PCC should be consid-
HUHGZKHQWKHSDWLHQWLVUHTXLULQJVWURQJRSLRLGVDQG
or symptoms persist or escalate following systematic 
oncology interventions.5 All but two patients within 
this data repository were receiving opioid analgesia. 
This raises the question as to whether this is sufficiently 
discriminative to aid timely referral. Clearer trigger 
points for patient identification are required to ensure 
maximum patient benefit from PCC and represent an 
area for further clarity.
The present findings support the role of PCC yet the 
limitations highlight the need for future work which 
should include a comparator group, detailed charac-
terisation of those referred including non- opioid and 
non- pharmacological strategies, geographical site and 
adverse events.
Additionally, accepting that there may be a limited 
number of centres offering PCC, assessing innova-
tive methods for remote consultations would be a 
key line of exploration. Finally, seeking wider inter-
national consensus on routinely recording specific 
patient- related outcome measures for PCC would 
enhance numbers and therefore the robustness of 
recommendations.
cOnclusIOn
The present findings support the role of PCC as an 
effective and safe treatment for cancer- related pain. 
We propose that patients who have pain which may be 
adequately treated by PCC should be considered for 
this at the earliest opportunity, rather than progressing 
through multiple types of analgesia which may be 
suboptimal but also have side effects related to these. 
Patients were often referred late in their disease and 
potentially the full benefit of this procedure was not 
realised; it is not clear if this observation was specific 
just to the UK or reflects wider practice. Further work 
is needed to fully elucidate this and to assess potential 
wider benefits of PCC.
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